Pyruvate Kinase Deficiency Market By Treatment Type (Targeted Disease-Modifying Therapies, Blood Transfusion and Supportive Care, Iron Overload and Complication Management, Splenectomy and Procedure-Based Management, Stem Cell Transplantation and Other Advanced Therapies); By Diagnosis / Testing (Genetic Testing, Pyruvate Kinase Activity Assays, Complete Blood Count and Blood Smear Testing, Other Biochemical and Hemolysis Tests); By End User (Hospitals & Specialty Clinics, Rare Blood Disorder & Hematology Centers, Research Institutes, Home Healthcare Services); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Pyruvate Kinase Deficiency Market: Targeted Therapies Transform Lifelong Care

The Global Pyruvate Kinase Deficiency Market was valued at USD 1.12 billion in 2025 and is projected to reach USD 2.03 billion by 2032, expanding at a CAGR of 8.96% during 2026–2032.

 

Pyruvate kinase deficiency is an ultra-rare inherited red blood cell disorder with a diagnosed prevalence of approximately 3.2–8.5 cases per million people in Western populations, while the total prevalence including undiagnosed cases may reach up to 51 cases per million. The condition can present from birth at an estimated frequency of around 6.5 cases per million births, creating a lifelong treatment requirement for affected patients.

 

Clinical burden is driven by chronic hemolytic anemia and associated complications. Many patients retain only 5%–25% of normal pyruvate kinase enzyme activity, while hemoglobin levels can fall to approximately 4–10 g/dL. Biliary events occur in around 38.2% of patients, spleen-related disorders in 24.7%, and cardiac complications in about 20.2%, increasing the need for transfusion support, iron management, splenic interventions, and long-term hematology care.

 

Treatment is moving beyond supportive care toward disease-targeted pyruvate kinase activation. Agios Pharmaceuticals’ PYRUKYND (mitapivat) became the first approved pyruvate kinase activator for adults with PKD and generated approximately USD 54 million in worldwide net revenue in 2025. Development is also extending into pediatric treatment through the ACTIVATE-Kids program, while other PK activators such as etavopivat and tebapivat remain under clinical evaluation across hemolytic disorders.

 

Market expansion through 2032 will be supported by the large undiagnosed patient pool, lifelong complication burden, wider PKLR genetic testing, commercial uptake of mitapivat, pediatric treatment expansion, and continued development of targeted and gene-based therapies.

 

Revenue Leaders and Emerging Growth Pockets Reshaping the PKD Market

By Treatment Type

Leading Subsegment – Targeted Disease-Modifying Therapies

Targeted Disease-Modifying Therapies lead the treatment segment with an estimated 41 Targeted disease-modifying therapies lead the Pyruvate Kinase Deficiency Market with an estimated 41% share, generating approximately USD 0.459 billion in 2025 revenue, and are projected to expand at a CAGR of 10.65% during 2026–2032. Growth is driven by the clinical adoption of oral pyruvate kinase activators such as mitapivat (Pyrukynd), which increase residual enzyme activity and restore ATP production in red blood cells. Improved cellular energy reduces hemolysis and positions targeted therapy as an important long-term treatment approach.

Fastest-Growing Subsegment – Stem Cell Transplantation and Advanced Therapies

Stem Cell Transplantation and Other Advanced Therapies accounted for an estimated 6% of the Pyruvate Kinase Deficiency Market, generating approximately USD 0.067 billion in 2025, and are projected to expand at the fastest CAGR of 12.65% during 2026–2032. Allogeneic HSCT remains the only established curative option for severe transfusion-dependent PKD, particularly in younger patients, while mitapivat provides a disease-modifying alternative. Emerging lentiviral gene therapy and gene-editing approaches could further reshape treatment by offering autologous curative strategies with fewer donor-related risks.

 

By Diagnosis / Testing

Leading and Fastest-Growing Subsegment – Genetic Testing

Genetic testing is estimated to lead the diagnosis segment with a 34.5% share, generating approximately USD 0.386 billion in 2025, and is projected to expand at the fastest CAGR of 10.48% during 2026–2032. Its dominance in the Pyruvate Kinase Deficiency Market is supported by the need to confirm PKLR gene mutations, resolve inconclusive enzyme assays, identify affected family members, and support treatment planning. Growing use of molecular diagnostics and genotype-based therapeutic decisions is further increasing testing demand.

 

By End User

Leading Subsegment – Hospitals & Specialty Clinics

Hospitals & Specialty Clinics account for an estimated 58% share of the Pyruvate Kinase Deficiency Market, generating approximately USD 0.650 billion in 2025 revenue, and are projected to expand at a CAGR of 8.17% during 2026–2032. Their dominance is supported by the need for specialized PKLR genetic testing, enzyme assays, transfusion management, splenectomy, gallstone-related procedures, and long-term hematology monitoring. Growing use of disease-modifying therapies, including FDA-approved mitapivat, is further increasing treatment-related revenue across specialized hospital and hematology care settings.

Fastest-Growing Subsegment – Research Institutes

Research institutes accounted for an estimated 11% of the Pyruvate Kinase Deficiency Market, generating approximately USD 0.123 billion in 2025, and are projected to expand at the fastest end-user CAGR of 10.77% during 2026–2032. Growth is supported by increasing involvement in PKD clinical trials, gene-therapy research, natural-history studies, and international patient registries. Research centers also contribute to evaluating therapies such as mitapivat, investigating PKLR-targeted gene approaches, and developing standardized diagnostic and disease-management guidelines.

 

By Geography

Leading Region – North America

North America leads the Pyruvate Kinase Deficiency Market with an estimated 41% share, representing approximately USD 0.459 billion in 2025 revenue, and is projected to expand at a CAGR of 7.81% during 2026–2032. Regional growth is supported by improving genetic diagnosis, specialized hematology care, and greater disease recognition. Persistent underdiagnosis caused by variable symptoms and difficult-to-detect PKLR mutations creates additional diagnostic opportunity, while founder effects and higher disease concentration within specific North American populations expand demand for targeted testing and treatment.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific represents an estimated 20% share of the Pyruvate Kinase Deficiency Market, generating approximately USD 0.224 billion in 2025 revenue, and is projected to expand at the fastest regional CAGR of 11.51% during 2026–2032. Growth is being supported by improving access to genetic testing and hematology services, rising diagnosis of rare inherited blood disorders, and greater awareness of PKD. Expanding specialist treatment networks and government initiatives for rare diseases are also improving patient identification and access to targeted PKD therapies across the region.

 

Commercial Leadership and Emerging Competition in Targeted PKD Care

Agios Pharmaceuticals – Commercial Leader in Disease-Modifying PKD Therapy

Agios Pharmaceuticals holds the strongest commercial position in the Pyruvate Kinase Deficiency Market through PYRUKYND® (mitapivat), the first approved disease-modifying therapy specifically targeting the underlying metabolic defect in adults with PK deficiency. The FDA approved PYRUKYND in February 2022 for hemolytic anemia in adults with PK deficiency, giving Agios an early-mover advantage in a disease that had historically been managed primarily through transfusions, splenectomy, and complication management. The drug also carries U.S. orphan-drug exclusivity for the approved PKD indication through February 2029.

Clinical efficacy provides the main foundation for Agios' position. In patients who were not regularly transfused, 40% of mitapivat-treated patients achieved the predefined sustained hemoglobin response compared with 0% receiving placebo. Among regularly transfused patients, 33% achieved the predefined reduction in transfusion burden, including 22% who became transfusion-free during the assessed period.

Commercial uptake has also become measurable. Agios reported USD 54.0 million in worldwide PYRUKYND net revenue during 2025, while fourth-quarter revenue reached USD 20.0 million. In Q3 2025, the company reported 149 U.S. patients on therapy and 262 unique patient prescription-enrollment forms. Agios is also developing mitapivat for pediatric PK deficiency through its Phase 3 ACTIVATE-Kids and ACTIVATE-KidsT programs, extending its PKD franchise beyond the currently approved adult population.

Rocket Pharmaceuticals – Leading Gene-Therapy Developer with a Potential Curative Approach

Rocket Pharmaceuticals represents the most advanced company-led gene-therapy effort in PKD through RP-L301, an investigational ex-vivo lentiviral gene therapy designed to introduce a functional copy of the PKLR gene into a patient's own hematopoietic stem cells. The program has received FDA RMAT and Fast Track designations, EMA PRIME designation, and orphan-drug designation in both the U.S. and Europe, reflecting its potential relevance for severe PKD.

Early clinical results demonstrated the potential of the approach. Rocket's Phase 1 study treated four patients—two adults and two pediatric patients. With follow-up extending to 36 months in adults and 12 months in pediatric patients, all four showed sustained clinically meaningful hemoglobin improvement, three of four achieved hemoglobin normalization, and none required red-blood-cell transfusions after neutrophil engraftment. No drug-related serious adverse events were reported in that dataset.

The program's commercial outlook is currently more uncertain than Agios'. Rocket disclosed in its 2026 first-quarter filing that it is no longer allocating internal resources to RP-L301 and does not currently plan to initiate the proposed 10-patient Phase 2 pivotal study. The company is instead exploring external partnership options that could provide a path forward for the program.

Other Companies Supporting the PKD Diagnostic and Development Ecosystem

• Labcorp / Invitae – Provides a red-blood-cell membrane disorders and enzymopathies genetic panel that includes PKLR, supporting molecular confirmation of PK deficiency and differential diagnosis of hereditary hemolytic anemia.

• Quest Diagnostics / Blueprint Genetics – Blueprint Genetics, a Quest Diagnostics subsidiary, includes PKLR in its Anemia Panel, supporting next-generation sequencing and variant interpretation for inherited anemia disorders.

• CENTOGENE GmbH – Has supported Agios' PKD clinical-development programs through centralized laboratory services and PKLR genetic testing, including work associated with the pediatric ACTIVATE-Kids and ACTIVATE-KidsT studies.

 

Analyst Commentary: Precision Hematology Opens New Commercial Pathways

The Pyruvate Kinase Deficiency Market is moving from long-term supportive management toward a more targeted rare-disease treatment model built around molecular diagnosis and disease-modifying therapy. The strongest commercial opportunities are emerging around wider PKLR genetic testing, earlier patient identification, broader use of pyruvate kinase activators, pediatric treatment expansion, and next-generation therapeutic approaches that could reduce dependence on transfusions and splenectomy. As diagnosis improves and more previously unidentified patients enter specialist care, revenue growth is expected to shift increasingly toward high-value targeted therapies and precision hematology services.

 

Pyruvate Kinase Deficiency Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.12 Billion
Revenue Forecast in 2032	USD 2.03 Billion
Overall Growth Rate	CAGR of 8.96% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Diagnosis / Testing, By End User, By Geography
By Treatment Type	Targeted Disease-Modifying Therapies, Blood Transfusion and Supportive Care, Iron Overload and Complication Management, Splenectomy and Procedure-Based Management, Stem Cell Transplantation and Other Advanced Therapies
By Diagnosis / Testing	Genetic Testing, Pyruvate Kinase Activity Assays, Complete Blood Count and Blood Smear Testing, Other Biochemical and Hemolysis Tests
By End User	Hospitals & Specialty Clinics, Rare Blood Disorder & Hematology Centers, Research Institutes, Home Healthcare Services
Key Companies	Agios Pharmaceuticals, Rocket Pharmaceuticals, Labcorp / Invitae, Quest Diagnostics / Blueprint Genetics, CENTOGENE GmbH
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Market expansion through 2032 will be supported by the large undiagnosed patient pool, lifelong complication burden, wider PKLR genetic testing, commercial uptake of mitapivat, pediatric treatment expansion, and continued development of targeted and gene-based therapies.
Customization Option	Available upon request